PL1965797T3 - Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem - Google Patents

Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem

Info

Publication number
PL1965797T3
PL1965797T3 PL06838621T PL06838621T PL1965797T3 PL 1965797 T3 PL1965797 T3 PL 1965797T3 PL 06838621 T PL06838621 T PL 06838621T PL 06838621 T PL06838621 T PL 06838621T PL 1965797 T3 PL1965797 T3 PL 1965797T3
Authority
PL
Poland
Prior art keywords
dizziness
reduction
side effect
pirfenidone
effect associated
Prior art date
Application number
PL06838621T
Other languages
English (en)
Inventor
Cynthia Y Robinson
Jeffery Stuart Loutit
Michelle M Freemer
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1965797(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of PL1965797T3 publication Critical patent/PL1965797T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
PL06838621T 2005-12-02 2006-11-29 Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem PL1965797T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74197605P 2005-12-02 2005-12-02
EP06838621A EP1965797B1 (en) 2005-12-02 2006-11-29 Reduction of dizziness, a side effect associated with pirfenidone therapy
PCT/US2006/045750 WO2007064738A1 (en) 2005-12-02 2006-11-29 Methods of reducing adverse events associated with pirfenidone therapy

Publications (1)

Publication Number Publication Date
PL1965797T3 true PL1965797T3 (pl) 2011-07-29

Family

ID=37807840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06838621T PL1965797T3 (pl) 2005-12-02 2006-11-29 Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem

Country Status (13)

Country Link
US (1) US20070203202A1 (pl)
EP (2) EP1965797B1 (pl)
JP (3) JP5175740B2 (pl)
AT (1) ATE497766T1 (pl)
CA (1) CA2631646C (pl)
CY (1) CY1111355T1 (pl)
DE (1) DE602006020070D1 (pl)
DK (1) DK1965797T3 (pl)
ES (2) ES2565190T3 (pl)
PL (1) PL1965797T3 (pl)
PT (1) PT1965797E (pl)
SI (1) SI1965797T1 (pl)
WO (1) WO2007064738A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
JP2010513320A (ja) * 2006-12-18 2010-04-30 インターミューン インコーポレイテッド ピルフェニドン治療を患者に提供する方法
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CA2691379C (en) 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
CN103561741A (zh) * 2011-03-08 2014-02-05 奥斯拜客斯制药有限公司 取代的n-芳基吡啶酮
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
WO2021107060A1 (ja) * 2019-11-27 2021-06-03 塩野義製薬株式会社 ピルフェニドンの副作用を軽減するための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2004110245A2 (en) * 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
US20070203202A1 (en) 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy

Also Published As

Publication number Publication date
ES2385935T3 (es) 2012-08-03
EP1965797B1 (en) 2011-02-09
JP5175740B2 (ja) 2013-04-03
US20070203202A1 (en) 2007-08-30
HK1151726A1 (en) 2012-02-10
EP2316453B1 (en) 2016-01-06
SI1965797T1 (sl) 2011-03-31
JP2012229275A (ja) 2012-11-22
ATE497766T1 (de) 2011-02-15
CA2631646C (en) 2016-07-26
HK1123213A1 (en) 2009-06-12
EP1965797A1 (en) 2008-09-10
CY1111355T1 (el) 2015-08-05
CA2631646A1 (en) 2007-06-07
WO2007064738A1 (en) 2007-06-07
DE602006020070D1 (de) 2011-03-24
JP2009518293A (ja) 2009-05-07
PT1965797E (pt) 2011-05-12
JP2015061888A (ja) 2015-04-02
DK1965797T3 (da) 2011-05-02
EP2316453A1 (en) 2011-05-04
ES2565190T3 (es) 2016-04-01

Similar Documents

Publication Publication Date Title
CY1111355T1 (el) Μειωση της ζαλης, μια παρενεργεια που συσχετιζεται με την θεραπεια πιρφενιδονης
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
CA2404387A1 (en) Theanine compositions for promoting sleep
FR13C0062I1 (pl)
MX2009006007A (es) Profarmacos y metodos para hacer y usar los mismos.
WO2006084139A3 (en) An implantable interferon-containing device
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
EP2043637B8 (en) Methods and medicaments for administration of ibuprofen
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TNSN07474A1 (en) Dosage regimen for prasugrel
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2008091704A3 (en) Treatment of cushing's syndrome and autism
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2007144889A3 (en) Treatment of neurofibromatosis
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.